Donatella Negri

List of Publications by Year
in descending order

67 papers	1,884 citations	293460 24 h-index	340414 39 g-index
70 all docs	70 docs citations	70 times ranked	2676 citing authors

#	Article	IF	Citations
1	Seasonal Betacoronavirus Antibodiesâ€™ Expansion Post-BNT161b2 Vaccination Associates with Reduced SARS-CoV-2 VoC Neutralization. Journal of Clinical Immunology, 2022, 42, 448-458.	2.0	7
2	Persistent immunogenicity of integrase defective lentiviral vectors delivering membrane-tethered native-like HIV-1 envelope trimers. Npj Vaccines, 2022, 7, 44.	2.9	2
3	Robust Neutralizing Antibodies to SARS-CoV-2 Develop and Persist in Subjects with Diabetes and COVID-19 Pneumonia. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1472-1481.	1.8	36
4	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. Viruses, 2021, 13, 355.	1.5	17
5	Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models. Cells, 2021, 10, 845.	1.8	4
6	Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. Nature Communications, 2021, 12, 2670.	5.8	297
7	Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization. Molecular Therapy - Methods and Clinical Development, 2021, 23, 263-275.	1.8	4
8	Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency. Frontiers in Immunology, 2021, 12, 750386.	2.2	6
9	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. Npj Vaccines, 2020, 5, 107.	2.9	11
10	Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza. Viruses, 2020, 12, 1460.	1.5	4
11	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. Npj Vaccines, 2020, 5, 36.	2.9	12
12	Development and Preclinical Evaluation of an Integrase Defective Lentiviral Vector Vaccine Expressing the HIVACAT T Cell Immunogen in Mice. Molecular Therapy - Methods and Clinical Development, 2020, 17, 418-428.	1.8	10
13	Skeletal Muscle Is an Antigen Reservoir in Integrase-Defective Lentiviral Vector-Induced Long-Term Immunity. Molecular Therapy - Methods and Clinical Development, 2020, 17, 532-544.	1.8	18
14	Enzyme-linked immunospot assay to monitor antigen-specific cellular immune responses in mouse tumor models. Methods in Enzymology, 2020, 632, 457-477.	0.4	4
15	Persistence of Integrase-Deficient Lentiviral Vectors Correlates with the Induction of STING-Independent CD8+ T Cell Responses. Cell Reports, 2019, 26, 1242-1257.e7.	2.9	23
16	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. Communications Biology, 2018, 1, 134.	2.0	26
17	Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens. Frontiers in Immunology, 2018, 9, 171.	2.2	31
18	Intranasal Administration of Integrase Defective Lentiviral Vectors Expressing mAbs Protects from H5 Influenza Virus Challenge In Vivo. Open Forum Infectious Diseases, 2017, 4, S520-S521.	0.4	1

#	Article	IF	Citations
19	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. Molecular Therapy, 2016, 24, 2021-2032.	3.7	41
20	Optimization of Mucosal Responses after Intramuscular Immunization with Integrase Defective Lentiviral Vector. PLoS ONE, 2014, 9, e107377.	1.1	12
21	Murine Granulocyteâ€“Macrophage Colony-Stimulating Factor Expressed from a Bicistronic Simian Immunodeficiency Virus-Based Integrase-Defective Lentiviral Vector Does Not Enhance T-Cell Responses in Mice. Viral Immunology, 2014, 27, 512-520.	0.6	1
22	Renal epithelial cells produce and spread HIV-1 via T-cell contact. Aids, 2014, 28, 2345-2353.	1.0	32
23	Mucosal Immunization with Integrase-Defective Lentiviral Vectors Protects against Influenza Virus Challenge in Mice. PLoS ONE, 2014, 9, e97270.	1.1	17
24	Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein. International Journal of Cancer, 2013, 132, 335-344.	2.3	38
25	Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. Retrovirology, 2012, 9, 69.	0.9	21
26	Integrase-defective lentiviral-vector-based vaccine: a new vector for induction of T cell immunity. Expert Opinion on Biological Therapy, 2011, 11, 739-750.	1.4	29
27	Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of dendritic cells. Vaccine, 2011, 29, 3465-3475.	1.7	17
28	Cholera Toxin Impairs the Differentiation of Monocytes into Dendritic Cells, Inducing Professional Antigen-Presenting Myeloid Cells. Infection and Immunity, 2011, 79, 1300-1310.	1.0	12
29	Toward Integrase Defective Lentiviral Vectors for Genetic Immunization. Current HIV Research, 2010, 8, 274-281.	0.2	18
30	Evaluation of HIV-1 integrase inhibitors on human primary macrophages using a luciferase-based single-cycle phenotypic assay. Journal of Virological Methods, 2010, 168, 272-276.	1.0	15
31	Polyclonal Treg cells enhance the activity of a mucosal adjuvant. Immunology and Cell Biology, 2010, 88, 698-706.	1.0	23
32	Transduction of Human Antigen-Presenting Cells with Integrase-Defective Lentiviral Vector Enables Functional Expansion of Primed Antigen-Specific CD8⁺ T Cells. Human Gene Therapy, 2010, 21, 1029-1035.	1.4	32
33	Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	20
34	Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine, 2010, 28, 4175-4180.	1.7	37
35	Integrase Defective, Nonintegrating Lentiviral Vectors. Methods in Molecular Biology, 2010, 614, 101-110.	0.4	12
36	Containment of Infection in Tat Vaccinated Monkeys After Rechallenge with a Higher Dose of SHIV89.6P_{cy243}. Viral Immunology, 2009, 22, 117-124.	0.6	18

#	Article	IF	Citations
37	Cholera Toxin andEscherichia coliHeat-Labile Enterotoxin, but Not Their Nontoxic Counterparts, Improve the Antigen-Presenting Cell Function of Human B Lymphocytes. Infection and Immunity, 2009, 77, 1924-1935.	1.0	29
38	Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine, 2009, 27, 4622-4629.	1.7	41
39	Development of antigen-specific T cells in mediastinal lymph nodes after intranasal immunization. Methods, 2009, 49, 334-339.	1.9	7
40	Viral outcome of simianâ€“human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys. Archives of Virology, 2008, 153, 463-472.	0.9	18
41	Macaca mulatta,fascicularisandnemestrinain AIDS vaccine development. Expert Review of Vaccines, 2008, 7, 1419-1434.	2.0	45
42	Characterization ofÎ±-Defensins Plasma Levels inMacaca Fascicularisand Correlations with Virological Parameters during SHIV89.6Pcy11Experimental Infection. AIDS Research and Human Retroviruses, 2007, 23, 287-296.	0.5	6
43	T cell receptor excision circles (TRECs) analysis during acute intrarectal infection of cynomolgus monkeys with pathogenic chimeric simian human immunodeficiency virus. Virus Research, 2007, 126, 86-95.	1.1	3
44	Successful Immunization with a Single Injection of Non-integrating Lentiviral Vector. Molecular Therapy, 2007, 15, 1716-1723.	3.7	79
45	Evaluation of a Self-Inactivating Lentiviral Vector Expressing Simian Immunodeficiency Virus Gag for Induction of Specific Immune Responsesin Vitroandin Vivo. Viral Immunology, 2006, 19, 690-701.	0.6	35
46	Identification of a cytotoxic T-lymphocyte (CTL) epitope recognized by Gag-specific CTLs in cynomolgus monkeys infected with simian/human immunodeficiency virus. Journal of General Virology, 2006, 87, 3385-3392.	1.3	11
47	A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1)HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice. Journal of General Virology, 2006, 87, 1625-1634.	1.3	26
48	Protective efficacy of a multicomponent vector vaccine in cynomolgus monkeys after intrarectal simian immunodeficiency virus challenge. Journal of General Virology, 2004, 85, 1191-1201.	1.3	63
49	T-cell-mediated protective efficacy of a systemic vaccine approach in cynomolgus monkeys after SIV mucosal challenge. Journal of Medical Primatology, 2004, 33, 251-261.	0.3	19
50	Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses. Journal of Immunological Methods, 2004, 291, 153-163.	0.6	6
51	Circular viral DNA detection and junction sequence analysis from PBMC of SHIV-infected cynomolgus monkeys with undetectable virus plasma RNA. Virology, 2004, 324, 531-539.	1.1	12
52	Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine, 2004, 22, 3258-3269.	1.7	70
53	SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. Journal of Medical Primatology, 2003, 29, 193-208.	0.3	51
54	HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials. DNA and Cell Biology, 2002, 21, 599-610.	0.9	35

#	Article	IF	Citations
55	Infection of simian B lymphoblastoid cells with simian immunodeficiency virus is associated with upregulation of CD23 and CD40 cell surface markers. Journal of Medical Virology, 2002, 68, 129-140.	2.5	6
56	ROLE OF CYTOKINES IN CANCER CACHEXIA IN A MURINE MODEL OF INTRACEREBRAL INJECTION OF HUMAN TUMOURS. Cytokine, 2001, 15, 27-38.	1.4	32
57	Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine, 2001, 19, 2862-2877.	1.7	135
58	Interference with complement regulatory molecules as a possible therapeutic strategy in HIV infection. Expert Opinion on Investigational Drugs, 2000, 9, 199-205.	1.9	3
59	Role of Cross-Linking Agents in Determining the Biochemical and Pharmacokinetic Properties of Mgr6â^'Clavin Immunotoxins. Bioconjugate Chemistry, 1998, 9, 372-381.	1.8	15
60	Comparison of three different methods for radiolabelling human activated T lymphocytes. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 497-504.	2.2	72
61	Efficiency of T cell triggering by anti-CD3 monoclonal antibodies (mAb) with potential usefulness in bispecific mAb generation. Cancer Immunology, Immunotherapy, 1997, 44, 257-264.	2.0	18
62	Approaches to implement bispecific antibody treatment of ovarian carcinoma. Cancer Immunology, Immunotherapy, 1997, 45, 187-189.	2.0	6
63	Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. , 1997, 73, 143-150.		25
64	Comparison of three different methods for radiolabelling human activated T lymphocytes. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 497-504.	3.3	12
65	In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. British Journal of Cancer, 1995, 72, 928-933.	2.9	30
66	Anti-tumor efficacy of an anti-epidermal-growth-factor- receptor monoclonal antibody and its F(abâ€²)2 fragment against high- and low-egfr-expressing carcinomas in nude mice. International Journal of Cancer, 1995, 62, 643-650.	2.3	24
67	Bispecific Antibody Targeted T Cell Therapy of Ovarian Cancer: Clinical Results and Future Directions. Stem Cells and Development, 1995, 4, 423-427.	1.0	42